

**IX BIOPHARMA LTD**  
(Incorporated in Singapore)  
(Company Registration No. 200405621W)

---

**ISSUE AND ALLOTMENT OF SHARES PURSUANT TO EXERCISE OF WARRANTS**

---

The Board of Directors (the “**Board**”) of iX Biopharma Ltd. (the “**Company**”), and together with its subsidiaries, the “**Group**”) wishes to announce that on 20 February 2026, the Company has allotted and issued 2,000 new ordinary shares pursuant to the exercise of warrants at the exercise price of S\$0.06 per warrant share, following which the number of issued shares of the Company has increased from 960,493,895 shares to 960,495,895 shares.

The new ordinary shares rank *pari passu* in all respects with the existing shares of the Company and are expected to be listed and quoted on the Singapore Exchange Securities Trading Limited on or around 24 February 2026. Pursuant to the aforesaid exercise of warrants, a cumulative total of 5,536,450 warrants, representing 9.63% of all warrants previously issued, have now been exercised and there are 51,973,029 outstanding warrants with an exercise price of S\$0.06 for each warrant share expiring on 18 July 2026.

Warrant holders may refer to <https://www.ixbiopharma.com/warrants/> for instruction on how to exercise their warrants.

**BY ORDER OF THE BOARD**

Eddy Lee Yip Hang  
Chairman & CEO  
20 February 2026

---

*This announcement has been reviewed by the Company’s Sponsor, UOB Kay Hian Private Limited (the “**Sponsor**”).*

*This announcement has not been examined or approved by the Singapore Exchange Securities Trading Limited (“**SGX-ST**”) and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.*

*The contact person for the Sponsor is Mr. Lance Tan, Senior Vice President, at 83 Clemenceau Avenue, #10-01, UE Square, Singapore 239920, telephone: (65) 6590 6881.*